Clinical Trial Design: Statistical Options/Challenges Panel Discussion

First International Summit on Interventional Pharmacoeconomics

David A. Hyman, MD, JD, on Inclusive Shared Savings

Sarah Yim, MD, on Clinical Development of Biosimilars: Lessons for Interventional Pharmacoeconomics

Gary L. Rosner, ScD, on Bayesian Non-Inferiority

Cost of Care

Health-Care Policy

The ASCO Post Staff

Blase N. Polite, MD, MPP, on Optimizing Cancer Policies in the United States

Blase N. Polite, MD, MPP, of the University of Chicago Medical Center, discusses his belief that, in the next few years, we can bend the cancer drug cost curve and tame health-care costs if physicians, pharmaceutical companies, payers, and government come together and agree on the value of treatments that improve survival and quality of life.

Focus on Optimized Dosing of Ibrutinib Panel Discussion

Mar

Today In Oncology

Clinical Trial Design: Statistical Options/Challenges Panel Discussion

Related Videos

David A. Hyman, MD, JD, on Inclusive Shared Savings

Sarah Yim, MD, on Clinical Development of Biosimilars: Lessons for Interventional Pharmacoeconomics

Gary L. Rosner, ScD, on Bayesian Non-Inferiority

Blase N. Polite, MD, MPP, on Optimizing Cancer Policies in the United States

Focus on Optimized Dosing of Ibrutinib Panel Discussion

Women More Likely to Survive Cancer—But Suffer More Severe Side Effects

Forgotten Lessons From South Africa

Romiplostim Improves Chemotherapy-Induced Thrombocytopenia in GI Cancers

Benmelstobart Plus Anlotinib in First-Line Treatment for PD-L1–Positive Advanced NSCLC

Optical Genome Mapping Detects Additional Genetic Variants in Nearly 20% of Individuals With Acute Leukemia